Navigation Links
Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted
Date:7/22/2014

BURLINGTON, Mass., July 22, 2014 /PRNewswire/ -- Decision Resources Group finds that over half of audited multiple sclerosis (MS) patients currently treated with Biogen Idec's oral disease-modify therapy (DMT) Tecfidera have ever experienced flushing and/or gastrointestinal events while on the therapy. However, few Tecfidera-treated patients are currently experiencing these side effects, signifying either their transient nature or the effective medical management of such events. In the end, fewer than 15 percent of surveyed neurologists felt that Tecfidera-related side effects were an obstacle to their prescribing of the product.

Other key findings from the ChartTrends: Multiple Sclerosis 2014 (US) report:

  • Anti-JC virus antibody testing: The majority of patients tested for anti-JC virus antibodies were treatment naive or were on a DMT other than Biogen Idec's Tysabri at the time of testing, supporting neurologists' reporting that the main driver of assay testing is related to patients' potential candidacy for Tysabri. However, patients (regardless of serostatus) were more likely to stay on their original DMT than switch to another DMT for up to two years after testing.
  • Market potential of emerging therapies: When neurologists hypothetically chose one of the emerging products profiled to switch the audit patient to, Biogen Idec's Plegridy—the product likely to reach the market first—was most frequently selected. Over half of surveyed neurologists believe that Plegridy is most likely to replace the interferon-beta-1a therapy Biogen Idec's Avonex, however patient-level data suggest that the impact of Plegridy is more likely to be spread across the platform injectable DMTs.

Comments from Decision Resour
'/>"/>

SOURCE Decision Resources Group
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
2. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
3. Sinovac to Host Conference Call to Report First Quarter 2012 Unaudited Financial Results
4. Sinovac Reports Unaudited First Quarter 2012 Financial Results
5. SCOLR Pharma Announces Unaudited Net Sales of Nutritional Products
6. 3SBio Inc. Schedules Unaudited Second Quarter 2012 Results
7. Techne Corporation Releases Unaudited Fourth Quarter And Fiscal Year 2012 Results
8. Sinovac to Host Conference Call to Report Second Quarter 2012 Unaudited Financial Results
9. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2012 Results
10. Sinovac Reports Unaudited Second Quarter 2012 Financial Results
11. Groupe Athena Inc., (OTC: GATA) Reports Audited Financials, Announces Record Revenue & Profits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Texas , Nov. 21, 2014  World Hemp ... containing low THC, announces they are now offering legal, ... to Charlotte,s Web type strains grown in medical marijuana ... other neurological disorders, such as Parkinson,s, MS, and spinal ... US laws to pass, because imported CBD Oil Is ...
(Date:11/21/2014)... , 21. November 2014 /PRNewswire/ ... hat heute bekannt gegeben, dass die ... EMA) die Kennzeichnung als Orphan-Medizinprodukt an ... des Unternehmens zur Behandlung von Fibrodysplasia ... seltene, stark beeinträchtigende genetische Krankheit, die ...
(Date:11/21/2014)... Nov. 20, 2014  Market research firm Kalorama information says ... The Buy, in the medical device industry.  The firm ... will produce just 3% growth this year, which led ... of product lines and entrance by acquisition into new ... medical devices, The Global Market for Medical Devices, ...
Breaking Medicine Technology:New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3Kalorama: 2014 The "Year of The Buy" in Medical Device Industry 2
... HONG KONG, Feb. 25, 2011 /PRNewswire-Asia-FirstCall/ -- Golden ... - 801.HK; 910801.TW), China,s leading integrated healthcare enterprise, ... acquire the remaining interests in the Group,s Chinese ... HK$90 million in shares.  Upon completion of the ...
... Calif., Feb. 24, 2011 Amgen (Nasdaq: AMGN ... 3 head-to-head trial that compared XGEVA ™ (denosumab) to ... skeletal-related events (SREs) in 1,901 men with prostate cancer and ... met its primary and secondary endpoints and demonstrated XGEVA,s superiority ...
Cached Medicine Technology:Golden Meditech Acquires Remaining Stake in Chinese Herbal Medicine Business 2Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 2Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 3Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 4Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 5Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 6Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 7Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 8Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer 9
(Date:11/22/2014)... NC (PRWEB) November 23, 2014 Cancer ... found a connection between intercellular communication tunnels and the ... read the full story on the Surviving Mesothelioma ... Center and the University of Minnesota have just released ... carry information and materials between cells. They found that ...
(Date:11/22/2014)... A classic black prom dress will never go ... suppliers, has unveiled its new items of black prom ... at a big discount, up to 70% off. People throughout ... new black prom dresses, made with the best materials, can ... of all customers, the company provides these beautiful outfits in ...
(Date:11/22/2014)... Today, Dylan Queen, a renowned brand in wedding ... the business offers a wide range of special occasion ... allowing them to create multiple looks easily. , According ... collection of chic wedding dresses has been prepared for ... discounted rates now. Dylan Queen can always create what ...
(Date:11/22/2014)... Discount-Dress.com is an important company in the dress industry. ... company’s online market share by a series of promotions. Recently, ... announced a bridesmaid dress promotion for the new year 2015. ... the dresses from this company are not only of high ... very good at manufacturing wedding dresses. Customers prefer to choose ...
(Date:11/22/2014)... "My friend went in for a mammogram ... said an inventor from Cambria Heights, N.Y. "To add ... second time because the first results were inaccurate. Her ... patent-pending MAMO EASY to offer a more comfortable way ... patient from the pain normally involved with this procedure. ...
Breaking Medicine News(10 mins):Health News:Study Links Cellular ‘Tunnels’ to Mesothelioma Proliferation, According to Surviving Mesothelioma 2Health News:New Black Prom Dresses from BellasDress.com 2Health News:Dylan Queen Introduces Its New Wedding Dresses 2Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2
... Storage and to Advance VSEL Research, NEW YORK, ... is pioneering the pre-disease collection, processing and long-term,storage of ... that,it has signed a collection center agreement with the ... Robin Smith, MD MBA, NeoStem,s Chairman and Chief Executive ...
... May 27 Isis,Pharmaceuticals, Inc. (Nasdaq: ISIS ... dollars from Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY ... the recently announced transaction,between Takeda Pharmaceutical Company Limited ... receive portions of future milestone and royalty,payments. This ...
... communities save time and money accepting automatic ... payments direct from resident bank accounts, PORTLAND, ... it,has added PaySimple, the leading provider of on-demand ... to help simplify resident billing,and collection for assisted ...
... join the Urban League of,Philadelphia for FREE Open House Clinics ... ages 19 and under, in,Pennsylvania,s Children,s Health Insurance Program (CHIP). ... the Urban League of Philadelphia, 121,S. Broad Street (between Chestnut ... Wednesday, May 28th, 6pm - 8pm Wednesday, ...
... at UCLA have identified a type of leukemia stem cell ... normal blood stem cells to become cancerous. , The discovery ... cells, attacking the disease at its very root and killing ... cells. The study appears in the May 22, 2008 issue ...
... Inc. (Nasdaq: EVVV ) today,announced that Robert Palmisano, ... the Goldman Sachs Twenty-Ninth Annual Global,Healthcare Conference on Tuesday, ... and 1:00 p.m. CT). The Goldman Sachs Twenty-Ninth Annual ... Niguel in,Dana Point, California., To access the webcast, ...
Cached Medicine News:Health News:NeoStem Signs Stem Cell Collection Agreement With University of Louisville Hospital 2Health News:NeoStem Signs Stem Cell Collection Agreement With University of Louisville Hospital 3Health News:Isis to Receive $4.6 Million From Alnylam 2Health News:Isis to Receive $4.6 Million From Alnylam 3Health News:Vigilan Offers PaySimple to Simplify Resident Billing and Collection 2Health News:Does Your Child Have Health Insurance? Urban League of Philadelphia Announces Free Open Houses for CHIP Enrollment 2Health News:UCLA researchers identify leukemia stem cells 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: